A Single-Arm, Multicenter, Open-Label Study Evaluating the Long-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024%, in Japanese Subjects With Open-Angle Glaucoma or Ocular Hypertension

Trial Profile

A Single-Arm, Multicenter, Open-Label Study Evaluating the Long-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024%, in Japanese Subjects With Open-Angle Glaucoma or Ocular Hypertension

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Jul 2016

At a glance

  • Drugs Latanoprostene bunod (Primary)
  • Indications Ocular hypertension; Open-angle glaucoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms JUPITER
  • Sponsors Bausch & Lomb
  • Most Recent Events

    • 25 Jul 2016 Status changed from active, no longer recruiting to completed according to results published in the Advances in Therapy.
    • 09 May 2016 According to a Nicox media release, results from this trial were presented at the Association for Research in Vision and Ophthalmology (ARVO) 2016 Annual Meeting.
    • 21 Aug 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top